A new Bay Area biotech is harnessing artificial intelligence to better understand and predict RNA structures in hopes of developing new therapeutics. […]
Out of stealth, Rezo Therapeutics seized on #JPM23 to tell its story. […]
“I had this kind of naive view that if you start with the same cell every time, and you run the same process, every time, then you’re going to end… […]
“The industry is learning that almost unlimited access to capital, chasing testing volume and adding cost on the back end, is not sustainable,” said Invitae CEO Ken Knight. […]
The balance of power between biotech startups and big pharma has shifted — but Bayer executive Marianne De Backer is still looking for deals. […]
In some of his first public remarks since getting booed on stage last month over Alzheimer’s drug remarks, Regeneron’s George Yancopoulos acknowledged in an interview he could’ve handled things differently. […]
What happened at #JPM23, biotech’s big reunion? Will this year be better than the last? And is it time to quit San Francisco? All that and more on the latest… […]
With the acquisition of machine learning firm InstaDeep, BioNTech is betting that AI will play a key role in the future of mRNA medicines. […]
Element’s machine can now read a whole human genome for as little as $200 — the cost of a couple trips to the grocery store. […]
SAN FRANCISCO — For months, drugmakers have been pleading with regulators to lower the bar for authorizing antibody drugs for Covid. The virus, they noted, had evolved fast enough to… […]
Copyright © 2022 Biotech Networks, LLC
